Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing email@example.com or calling +44 (0)1707 367554.
Discover the value of inhibiting IL-6 with RoACTEMRA in RA patients
By targeting IL-6 with RoACTEMRA, a selective IL-6 receptor antagonist, inflammation can be reduced leading to a decrease in local and systemic symptoms1,2
Adapted from Dayer JM et al. 2010 2
IL-6 signalling has been implicated in the following signs and symptoms associated with rheumatoid arthritis:
RoACTEMRA targets a broader range of IL-6 expressing inflammatory cells than either anti-TNFs or methotrexate (MTX)3
Adapted from Witte T, 20153
CVD, cardiovascular disease; IL-6R, interleukin-6 receptor; MTX, methotrexate; sIL-6R soluble interleukin-6 receptor; TNF, tumour necrosis factor.
- Scott LJ. Drugs 2017;77:1865–1879;
- Dayer JM and Choi E. Rheumatology 2010;49:15–24;
- Witte T. Clin Rheumatol. 2015;34:629–634;
- Choy E. Rheum Dis Clin North Am. 2004;30:405-415.
Date of preparation: September 2021